Toggle Menu

Press Room

MSKCC Risk Stratification Model in RCC Updated to Include Genomic Information

12/28/2018

The Memorial Sloan Kettering Cancer Center (MSKCC) risk stratification model in advanced renal cell carcinoma (RCC) currently used in clinical practice stratifies patients into risk groups of favorable, intermediate, and poor.

Cancer research legend urges patients to get multiple opinions

12/27/2018

National Cancer Institute Chief of Surgery Steven Rosenberg recommends seeking out multiple professional opinions to confirm a diagnosis and to figure out what your best options are.

Clinicopathological Features and Survival Data of Localized Renal Masses in Young Adults

12/26/2018

According to a study that was done by the Asian Pacific Journal of Cancer Prevention, the overall survival rate of young adults (ages 18-40 years old) with localized renal masses is 93.8%.

Optimizing Combinations Next Challenge in mRCC

12/21/2018

As the treatment paradigm for metastatic renal cell carcinoma (mRCC) continues to evolve, combination therapy is likely to be an important part of the future, said Bradley G. Somer, MD.

Future Directions for RCC Research

12/20/2018

Dr. Brian Rini and Dr. David McDermott explain what’s next in kidney cancer research.

Prognosis of renal cell carcinoma with bone metastases: Experience from a large cancer centre

12/20/2018

Bone metastases (BMs) are associated with significant morbidity and shorter survival in renal cell carcinoma (RCC). Our purpose was to identify prognostic factors for overall survival (OS) in RCC patients with BMs.

Immediate Surgery No Help in Metastatic RCC

12/14/2018

Treating metastatic kidney cancer with immediate cytoreductive nephrectomy (CN) did not ward off disease progression, the randomized SURTIME trial confirmed.

Life threatening toxicities of chemotherapies and immunomodulating medications

12/14/2018

Life threatening toxicities of chemotherapies and immunosuppressants can occur with varying frequency depending on the agent suspected and underlying patient risk factors. It is important for clinicians to remember that these medications can be the cause or contributor to many important complications that occur in the ICU.

Economic Burden of Metastatic Clear-Cell Renal Cell Carcinoma for French Patients Treated With Targeted Therapies

12/14/2018

Targeted therapies have transformed the treatment of metastatic clear-cell renal cell carcinoma (mccRCC). Despite the importance of mccRCC, studies on its economic burden in daily practice are sparse.

Changes in Renal Cell Carcinoma Pathologic Staging and Histologic Grading

12/13/2018

The most important prognostic factor when treating renal cell carcinoma (RCC) is tumor staging. Larger tumors (greater than 4 cm to 5 cm) need to be carefully assessed for the possibility of renal sinus invasion, according to a new review published Surgical Pathology Clinics.

Previous  |  1  |  2  |  3  |  4  |  5  |  6  |  7  |  8  |  9  |  10  |  11  |  12  |  13  |  14  |  15  |  16  |  17  |  18  |  19  |  20  |  21  |  22  |  23  |  24  |  25  |  26  |  27  |  28  |  29  |  30  |  31  |  32  |  33  |  34  |  35  |  36  |  37  |  38  |  39  |  40  |  41  |  42  |  43  |  44  |  45  |  46  |  47  |  48  |  49  |  50  |  51  |  52  |  53  |  54  |  55  |  56  |  57  |  58  |  59  |  60  |  61  |  62  |  63  |  64  |  65  |  66  |  67  |  68  |  69  |  70  |  71  |  72  |  73  |  74  |  75  |  76  |  77  |  78  |  79  |  80  |  81  |  82  |  83  |  84  |  85  |  86  |  87  |  88  |  89  |  90  |  91  |  92  |  93  |  94  |  95  |  96  |  97  |  98  |  99  |  100  |  101  |  102  |  103  |  104  |  105  |  106  |  107  |  108  |  109  |  110  |  111  |  112  |  113  |  114  |  115  |  116  |  117  |  118  |  119  |  120  |  121  |  122  |  123  |  124  |  125  |  126  |  127  |  128  |  129  |  130  |  131  |  132  |  133  |  134  |  135  |  136  |  137  |  138  |  139  |  140  |  141  |  142  |  143  |  144  |  145  |  146  |  147  |  148  |  149  |  150  |  151  |  152  |  153  |  154  |  155  |  156  |  157  |  158  |  159  |  160  |  161  |  162  |  163  |  164  |  165  |  166  |  167  |  168  |  169  |  170  |  171  |  172  |  173  |  174  |  175  |  176  |  177  |  178  |  179  |  180  |  181  |  182  |  183  |  184  |  185  |  186  |  187  |  188  |  189  |  190  |  191  |  192  |  193  |  194  |  195  |  196  |  197  |  198  |  199  |  200  |  201  |  202  |  203  |  204  |  205  |  206  |  207  |  208  |  209  |  210  |  211  |  212  |  213  |  214  |  215  |  216  |  217  |  218  |  219  |  220  |  221  |  222  |  223  |  224  |  225  |  226  |  227  |  228  |  229  |  230  |  231  |  232  |  233  |  234  |  235  |  236  |  237  |  238  |  239  |  240  |  241  |  242  |  243  |  244  |  245  |  246  |  247  |  248  |  249  |  250  |  251  |  252  |  253  |  254  |  255  |  256  |  257  |  258  |  259  |  260  |  261  |  262  |  263  |  264  |  265  |  266  |  267  |  268  |  269  |  270  |  271  |  272  |  273  |  274  |  275  |  276  |  277  |  278  |  279  |  280  |  281  |  282  |  283  |  284  |  285  |  286  |  287  |  288  |  289  |  290  |  291  |  292  |  293  |  294  |  295  |  296  |  297  |  298  |  299  |  300  |  301  |  302  |  303  |  304  |  305  |  306  |  307  |  308  |  309  |  310  |  311  |  312  |  313  |  314  |  315  |  316  |  317  |  318  |  319  |  320  |  321  |  322  |  323  |  324  |  325  |  326  |  327  |  328  |  329  |  330  |  331  |  332  |  333  |  334  |  335  |  336  |  337  |  338  |  339  |  340  |  341  |  342  |  343  |  344  |  345  |  346  |  347  |  348  |  349  |  350  |  351  |  352  |  353  |  354  |  355  |  356  |  357  |  358  |  359  |  360  |  361  |  362  |  363  |  364  |  Next
NeonCRM by Neon One